Summary
21 patients with acute myocardial infarction and ventricular arrhythmia of Lown class II–IIIB of acute onset received a short infusion of (50 mg/5 min) ajmaline (Gilurytmal®). 6 of the patients had normal kidney and liver function (Group 1), 4 patients had acute renal failure and hemodialysis treatment (Group 2), 4 patients had impaired hepatic function (Group 3), 3 patients had cardiogenic shock (Group 4), and 4 patients had been pretreated with phénobarbital for seizures for at least 5 days (Group 5). A distribution half-life of 6±1 min and an elimination half-life of 95±6 min was determined in Group 1. The total plasma clearance was significantly lower in patients with impaired liver or cardiac function and significantly higher in Group 5, whereas impaired renal function did not affect total plasma clearance. After short infusion, ventricular arrhythmia of Lown II–HIB completely disappeared for at least 16 to 36 min (mean: 19 min), which was associated with an ajmaline plasma level of 0.1–0.45 μg/ml. Additionally, steady-state plasma levels of ajmaline were determined after continuous infusion of 10–50 mg/h to 16 patients (Group 6) with ventricular arrhythmia of acute onset (Lown class IVA–V). Ventricular arrhythmia completely disappeared or at least changed to lower Lown classes at ajmaline plasma levels of 0.4–2.0 μg/ml.
The ajmaline plasma protein binding was 76±9%. Ajmaline had a special affinity to ai-acid glycoprotein.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Späth G. (1983): Die Antiarrhythmic Ajmalin und Prajmalinbitartrat, Kardiologische Reihe 2, de Gruyter, Berlin.
Bussmann W.-D., Hänel H.-J., Kaltenbach M. (1974): Die Wirkung von Ajmalin-bitartrat auf die ventrikuläre Extrasystolie beim frischen Herzirifarkt. Dtsch. Med. Wochenschr., 99, 2443–2447.
Chiale P.A., Przybylski J., Halpem M.S., Lazzari J.O., Elizari M.V., Rosenbaum M.B. (1977): Comparative effects of ajmaline on intermittent bundle branch block and the Wolff-Parkinson-White syndrome. Am. J. Cardiol, 39, 651–657.
Chiale P.A., Przybylski J., Laino R.A. et al. (1982): Usefulness of the ajmaline test in patients with latent bundle branch block. Am. J. Cardiol. 49, 21–26.
Grenadier E., Alpan G., Keidar S., Weiss D., Marmor A., Palant A. (1983): The efficacy of ajmaline in ventricular arrhythmias after failure of lidocaine therapy in the acute phase of myocardial infarction. Angiology, 34, 204–214.
Lengfelder W., Senges J., Rizos I., et al. (1985): Intraindividual comparison of intravenous ajmaline and quinidine in patients with sustained ventricular tachycardia: Effects on normal myocardium and on arrthythmia characteristics. Eur. Heart J., 6, 312–322.
Manz M., Lüderitz B. (1988): Notfalltherapie von ventrikulären Tachykardien: Lidocain versus Ajmalin. Dtsch. Med. Wochenschr., 113, 1317–1321.
Kleinsorge H., Gaida P. (1961): Ausscheidungsmengen und -geschwindigkeiten des Rauwolfia-Alkaloids Ajmalin nach verschiedenen Applikationsformen. Arzneimittelforsch., 11, 1100–1102.
Maurer H., Pfleger K. (1988): Toxicological detection of ajmaline, prajmaline and their metabolites integrated in a “general unknown” analysis procedure using GC/MS. Fresenius Z. Anal. Chem., 330, 459–460.
Annua M., Tikkanen R., Nieminen L. (1978): Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. Arzneimittelforsch., 3, 397–399.
Clemans S.D., Davison C., Koss R.F. et al. (1977): Agas chromatography-mass fragmentographic method for the assay of ajmaline and its monochloroacetyl ester. Arzneimittelforsch., 27, 1128–1130.
Shah R.A. et al. (1964): Spectrophotometry; determination of submicro quantities of ajmaline. Anal. Chim. Acta, 30, 576–584.
Spilker B., Shargel L., Koss R.F., Minatoya H. (1975): Cardiovascular effects and blood concentrations of ajmaline and its 17-monochloroacetate ester in cats. Arch. Int. Pharmacodyn. Ther., 216, 63–78.
Sybirska H., Gajdzinska H. (1972): Identifizierung und quantitative Bestimmung von Ajmalin im Sektionsmaterial. Arch. Toxikol., 28, 296–301.
Hori R., Okumura K., Inui K.I., et al. (1984): Quinidine induced rise in ajmaline plasma concentration. J. Pharm. Pharmacol., 36, 202–204.
Whitham J.B., Brown K.F. (1981): Ultrafiltration in serum protein binding determination. J. Pharm. Sci., 70, 146–150.
Chan K.K.H., Wnuck K. (1983): Microcomputer based pharmacokinetic programs for calculation absorption rate. Comput Progr. Biomed., 16, 27.
Eichelbaum M., Reetz K.-P., Schmidt E.K., Zekom C. (1986): The genetic polymorphism of sparteine metabolism. Xenobiotica, 16, 465–481.
Zekorn C. et al. (1985): Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin. Wochenschr., 63, 1180–1186.
Follath F., Ganzinger U., Schuetz E. (1983): Rehability of antiarrhythmic drug plasma concentration monitoring. Clin. Pharmacokin., 8, 63–82.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Köppel, C., Wagemann, A. & Martens, F. Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. Eur. J. Drug Metab. Pharmacokinet. 14, 161–167 (1989). https://doi.org/10.1007/BF03190857
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190857